595 / 1498
follicular lymphoma responding to
rituximab
plus chemotherapy
(PRIMA): a phase 3, randomised controlled trial.
Salles G et al
Lancet. 2011 Jan 1;377(9759):42-51
stratified HR=0.50
95% CI 0.39; 0.64
p
<.0001
Time (months)
Rituximab maintenance
N=505
Observation
N=513
6
0
12
18
24
30
36
Progression-free rate
0.8
0.6
0.4
0.2
0
1.0
82%
66%
Patients at risk
505
513
472
443
336
230
103
18
469
411
289
195
82
15